1PW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

HATE Application of:

Dario NERI et al.

Serial No.: 10/821,930

Group Art Unit: 1614

Filed: 12 April 2004

Examiner: Unknown

For: SPECIFIC BINDING MOLECULES FOR SCINTIGRAPHY, CONJUGATES CONTAINING THEM AND THERAPEUTIC METHOD FOR TREATMENT OF ANGIOGENESIS

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

## Timing and Fees

$\boxtimes$		er 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information losure statement is filed:				
		within three months of the filing date of a national application other than a CPA under § 1.53(d);				
		within three months of the actual filing date of the national phase of a PCT application; OR				
	$\boxtimes$	before the mailing of a first substantive office action (including after filing of an RCE).				
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ted in 37 C.F.R. § 1.97(b), but before the mailing date of:				
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and				

		is accompanied by:						
	·		the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR					
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).					
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:					
		a final	action under 37 C.F.R. § 1.113;					
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);					
		OR a r	notice of allowance under 37 C.F.R. § 1.311;					
	AND i	is filed on or before payment of the issue fee; AND is accompanied by:						
		the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).						
Statem	ents Ur	nder 37	C.F.R. 1.97(e)					
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or					
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.					
Cited 1	Materia	<u>ls</u>						
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120 ancestor application Serial No. <u>09/512,082</u> , on Form 892 by the Examiner and/o Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).						
			of materials listed but not attached were cited in an international search dated					
		Not re	quired by 37 CFR § 1.98.					
	$\boxtimes$	Copies	of the materials listed are attached (except for the foregoing).					

Non-Englis	h Language References					
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).					
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:					
	<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> </ul>					
	A = document defining the general state of the art					
	O = non-written disclosure P = intercalated document					
	T = document cited to understand the theory or principle underlying the invention					
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date					
	D = cited in the application					
	L = cited for another reason					
	& = publication of member of same patent family					
	Translation of other relevant information on foreign search report					
	[insert necessary translation here]					
Other Infor	mation .					
Payment of	Fees Due (If Any):					
☐ A c	heck for \$ covering the fee identified above is attached.					
Plea	ase charge to Deposit Account No. 13-3402 \$ for the fee identified above.					

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: ELLIS-0002-P02-C01

Date: August 15, 2005

AJZ:at

 $K:\label{lis-2} $$K:\Ellis-2\P2\c1\Information\ Disclosure\ Statement\ Aug\ 2005.doc$ 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/821,930 INFORMATION DISCLOSURE Filing Date 12 April 2004 STATEMENT BY APPLICANT First Named Inventor Dario NERI et al Group Art Unit 1614 (use as many sheets as necessary) Examiner Name Unknown Sheet of ELLIS-0002-P02-C01 Attorney Docket Number

Please type a plus sign (+) in

			U.S. P	ATENT DOCUMENTS		
Examiner Initials *	Cite No.1	U.S. Patent Document  Kind Code <sup>2</sup> Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY	
	1	4,894,326		MATSUURA et al.	01-16-1990	
	2	6,749,853		THORPE et al.	06-15-2004	
	3	6,394,952		ANDERSON et al.	05-28-2002	
	4	6,267,722		ANDERSON et al.	07-31-2001	
	5	5,177,015		MATSUURA et al.	01-05-1993	
	6	5,837,813		RUOSLAHTI et al.	11-17-1998	
	7	2004/0013640		ZARDI et al.	01-22-2004	
	8	2004/0001790		HILGER et al.	01-01-2004	

Examiner Initials*	Cite No.1	Foreign Patent Document				Date of Publication of	Pages, Columns, Lines,	
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T⁵
			<del>.</del>					

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.